Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Yujie Wang
Xinjiang Medical University
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
70
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Deutenzalutamide (Deuterated Enzalutamide), a Novel Androgen Receptor Inhibitor after Failure of Docetaxel and Abiraterone in Metastatic Castrate Resistant Prostate Cancer (mCRPC): Results from Therandomized Phase III HC-1119-04 Trial
Number of pages: 17
Posted: 28 Oct 2024
Chengyuan Gu
,
Xinghai Li
,
Lixin Hua
,
Ranlu Liu
,
Jun Li
,
Mingxing Qiu
,
Jianming Guo
,
Haiying Dong
,
Zhigang Ji
,
Liping Xie
,
Shaoxing Zhu
,
Xuhui Zhang
,
Peng Chen
,
Shusuan Jiang
,
Zhongquan Sun
,
Danfeng Xu
,
Hui Chen
,
Benkang Shi
, Yujie Wang,
Jinxian Pu
,
Frank Perabo
,
Yuanwei Chen
,
Dingwei Ye
and
HC-1119-04 Study Group
Fudan University, Hinova Pharmaceuticals Inc, Nanjing Medical University - Jiangsu Province Hospital, Tianjin Medical University, Chongqing Cancer Hospital, Government of the People's Republic of China - Sichuan Provincial People's Hospital, Fudan University - Zhongshan Hospital, Hangzhou Medical College - Zhejiang Provincial People's Hospital, Peking Union Medical College, Zhejiang University, Zhejiang Cancer Hospital, Shanxi Medical University, Xinjiang Medical University, Central South University - Hunan Cancer Hospital, Fudan University, Shanghai Jiao Tong University (SJTU), Harbin Medical University, Shandong University, Xinjiang Medical University, Soochow University, Hinova Pharmaceuticals Inc, Hinova Pharmaceuticals Inc, Fudan University - Department of Oncology and Independent
Downloads
70
(730,018)
View PDF
Download
Abstract:
Prostate cancer, mCRPC, androgen receptor (AR), clinical trial, phase 3
Feedback